Tumor antigen-specific T cell response enhancement

Tumor antigen-specific T cell response enhancement refers to immunological strategies designed to amplify the body’s ability to recognize and destroy cancer cells via T lymphocytes that selectively target tumor-associated or tumor-specific antigens. This can include adoptive cell transfer therapies (such as TCR-engineered T cells or tumor-infiltrating lymphocytes), therapeutic vaccines to stimulate antigen-specific T cells, or drugs (notably checkpoint inhibitors) that counteract mechanisms of immune evasion by tumors. The effectiveness of such approaches depends on successful antigen presentation, priming of T cells by antigen-presenting cells, the avidity and specificity of T cell receptor recognition, and overcoming tumor-induced immune suppression within the tumor microenvironment [1][2][4][6][7]. Key biomarkers for effective response and patient selection include CXCL13, CD200, and ENTPD1, which help identify tumor-reactive T cells [1]. Safety concerns primarily arise from the possibility of targeting antigens shared with normal cells, leading to collateral tissue damage, or from overactivation of the immune system [2][6].

Other names

Tumor antigen-specific T cell immunotherapyTumor antigen-specific T cell activationTumor antigen-specific T cell enhancement

Enhancement of T cell recognition and killing of tumor cells via antigen-specific T cell receptor engagement [1][2][4][6]; Modulation of immune checkpoint pathways to prevent T cell exhaustion or anergy [2][6]; Priming and expansion of tumor-reactive T cells by antigen-presenting cells or vaccination [1][4][5]